Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study-Reference-Cited by-同舟云学术

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study

Published:2021-08-20 Issue:24 Volume:127 Page:4585-4593
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Harding James J.¹²^ORCID,Yang Tsai‐Sheng³,Chen Yen‐Yang⁴,Feng Yin‐Hsun⁵,Yen Chia‐Jui⁶,Ho Ching‐Liang⁷,Huang Wen‐Tsung⁸,El Dika Imane¹²,Akce Mehmet⁹^ORCID,Tan Benjamin¹⁰,Cohen Stacey A.¹¹,Meyer Timothy¹²,Sarker Debashis¹³,Lee Dae‐Won¹⁴,Ryoo Baek‐Yeol¹⁵,Lim Ho Yeong¹⁶,Johnston Amanda¹⁷,Bomalaski John S.¹⁷,O’Reilly Eileen M.¹²^ORCID,Qin Shukui¹⁸,Abou‐Alfa Ghassan K.¹²^ORCID

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York

2. Weill Cornell Medical College New York New York

3. Internal Medicine Linkou Chang Gung Medical Foundation Taoyuan City Taiwan

4. College of Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung City Taiwan

5. Internal Medicine Chi Mei Medical Center Tainan City Taiwan

6. Department of Internal Medicine National Cheng Kung University Hospital Tainan Taiwan

7. Division of Hematology Department of Medicine National Defense Medical Center, Tri‐Service General Hospital Taipei City Taiwan

8. Department of Medicine Chi Mei Medical Center‐Liouying Tainan City Taiwan

9. Department of Hematology and Oncology Winship Cancer InstituteEmory University School of Medicine Atlanta Georgia

10. Department of Medicine Washington University in St Louis St Louis Missouri

11. Oncology University of Washington Seattle Washington

12. Oncology Royal Free Hospital London United Kingdom

13. Department of Medicine Guys Hospital London United Kingdom

14. Internal Medicine Seoul National University Hospital Seoul Korea

15. Department of Medicine, Asan Medical Center University of Ulsan College of Medicine Seoul Korea

16. Division of Hematology‐Oncology Department of Medicine Samsung Medical Center Seoul Korea

17. Polaris Pharmaceuticals, Inc San Diego California

18. Cancer Center Bayi Hospital of Nanjing Chinese Medicine University Nanjing China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33870

Reference38 articles.

1. Arginine dependence of tumor cells: targeting a chink in cancer’s armor

2. Amino acid auxotrophy as a system of immunological control nodes

3. Cancer metabolism: a therapeutic perspective

4. Pegylated arginine deiminase (ADI‐SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo;Ensor CM;Cancer Res,2002

5. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study;Signal Transduction and Targeted Therapy;2023-09-27

2. Arginine regulates HSPA5/BiP translation through ribosome pausing in triple-negative breast cancer cells;British Journal of Cancer;2023-06-29

3. Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment;International Journal of Molecular Sciences;2023-06-26

4. WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma;Frontiers in Oncology;2022-12-02

5. Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021;Expert Opinion on Investigational Drugs;2022-05-26